An official website of the United States government
Home
Name
NovoTTF-100A system
Alternate Names
NovaTTF
OPTUNE
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Brain (Recurrent Glioblastoma Multiforme) GBM
Histology
None
Remarks
May 31, 2019: FDA has approved a tumor-treating fields device in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, or metastatic malignant pleural mesothelioma.
The device, the NovoTTF-100L System (Novocure), is the first treatment for MPM approved by the FDA in 15 years, since pemetrexed was approved in 2004. TTF therapy uses electric fields to disrupt solid tumor cancer cell division.
The NovoTTF-100A system treats recurrent glioblastoma multiforme (GBM). The NovoTTF-100A system is a first-of-its-kind treatment that fights cancerous brain tumors using electrical energy fields. It is a portable battery or power-supply operated device which produces chagning electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the head of the patient by electrically-insulated surface electrodes. TTFields stop the growth of tumor cells resulting in cell death of the rapidly dividing cancer cells. The frequency of the TTFields used for a particular treatment is specific to the size of the cell type being treated. This system is intended as a treatment for adult patients (22 years of age or older) with confirmed glioblastoma multiforme, following confirmed recurrence in an upper region of the brain (supratentorial) after receiving chemotherapy. The device is intended to be used as a stand-alone treatment, and is intended as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.
The device, the NovoTTF-100L System (Novocure), is the first treatment for MPM approved by the FDA in 15 years, since pemetrexed was approved in 2004. TTF therapy uses electric fields to disrupt solid tumor cancer cell division.
The NovoTTF-100A system treats recurrent glioblastoma multiforme (GBM). The NovoTTF-100A system is a first-of-its-kind treatment that fights cancerous brain tumors using electrical energy fields. It is a portable battery or power-supply operated device which produces chagning electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the head of the patient by electrically-insulated surface electrodes. TTFields stop the growth of tumor cells resulting in cell death of the rapidly dividing cancer cells. The frequency of the TTFields used for a particular treatment is specific to the size of the cell type being treated. This system is intended as a treatment for adult patients (22 years of age or older) with confirmed glioblastoma multiforme, following confirmed recurrence in an upper region of the brain (supratentorial) after receiving chemotherapy. The device is intended to be used as a stand-alone treatment, and is intended as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.
Coding
This drug should be coded
